SoMex Research & Health
Pvt. Ltd.
+91-141-2504996           
banner11 banner22 banner33 banner44

Clinical Trials » Ongoing Trials


CLDK378A2301:
A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer (Phase-III)- Principal Investigator- Dr. Naresh Somani

Protocol No. WOC/AMS/CT-44/14:
A Surveillance Study on the Antibiotic susceptibility pattern of bacterial isolates collected from patients at various Indian Tertiary Care Hospitals (ASPIRE INDIA)

Project # MYL-1402O-3001:
Multicentre, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With AvastinĀ®, in the First -line treatment of Patient with Stage IV Non-Squamous Non-Small Cell Lung Cancer.

Protocol No: CLDK378AIN01:
A real-world, open-label, multi-center, prospective, non-interventional (observational) study to evaluate the effectiveness and tolerability of ceritinib in Indian pativvents with ALK positive metastatic non-small cell lung cancer who have progressed or are intolerant to crizotinib.

Protocol Title: CPZP034AIC04 Parachute:
Pazopanib Real-world Assessment of Clinical effectiveness and safety in patients who have Undergone treatment in different settings in advanced renal cell carcinoma; a prospective, non-interventional, observation study.


Investigator Initiative Clinical Trial


A pilot study (Phase II Trial) of Cetuximab with Afatinib as First-Line Therapy in patients With Advanced Non-Sequamous Non-Samall-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Multations positive patients. - PI Dr. Naresh Somani

A pilot study (Phase II Trial ) of Gefitinib/Afatinib with pemetrexed as First-Line therapy in Patients with advanced Non-squamous Non-Small-Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutations positive patients. PI Dr. Naresh Somani

A pilot study (Phase II Trial ) of Nivolumab with Pemetrexed as Palliative Chemotherapy in Patients with advanced Non-Small-Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutations positive patients. PI Dr. Naresh Somani